Outlook Therapeutics (OTLK) Other Non-Current Liabilities (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Other Non-Current Liabilities of $722229.0 for Q1 2026, down 86.75% year-over-year from $5.5 million in Q1 2025, and down 90.45% quarter-over-quarter from $7.6 million in Q4 2025.
Outlook Therapeutics (OTLK) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Other Non-Current Liabilities for 12 consecutive years, with $722229.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 86.75% year-over-year to $722229.0; the TTM figure through Mar 2026 stood at $722229.0 (down 86.75% YoY), while the FY2025 annual figure was $4.8 million, down 91.93% from the prior year.
- Other Non-Current Liabilities eased to $722229.0 in Q1 2026 per OTLK's latest filing, from $7.6 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $139.2 million in Q1 2024 and bottomed at $6219.0 in Q3 2023.
- Historically, Other Non-Current Liabilities has averaged $19.5 million across 5 years, with a median of $722229.0 in 2026.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities sank 97.23% — and 2024, when it soared 1684331.11%.
- Outlook Therapeutics' Other Non-Current Liabilities stood at $26878.0 in 2022, then jumped by 121.6% to $59561.0 in 2023, then jumped by 31508.15% to $18.8 million in 2024, then sank by 59.84% to $7.6 million in 2025, then slumped by 90.45% to $722229.0 in 2026.
- Business Quant data shows OTLK's Other Non-Current Liabilities at $722229.0 in Q1 2026, $7.6 million in Q4 2025, and $4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 722,229.00 |
| Dec 31, 2025 | 7.56 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 7.45 Mn |
| Mar 31, 2025 | 5.45 Mn |
| Dec 31, 2024 | 18.83 Mn |
| Sep 30, 2024 | 59.10 Mn |
| Jun 30, 2024 | 87.95 Mn |
| Mar 31, 2024 | 139.18 Mn |
| Dec 31, 2023 | 59,561.00 |
| Sep 30, 2023 | 6,219.00 |
| Jun 30, 2023 | 20,012.00 |
| Mar 31, 2023 | 8,263.00 |
| Dec 31, 2022 | 26,878.00 |
| Sep 30, 2022 | 57,138.00 |
| Jun 30, 2022 | 68,319.00 |
| Mar 31, 2022 | 298,033.00 |
| Dec 31, 2021 | 273,020.00 |
| Sep 30, 2021 | 522,918.00 |
| Jun 30, 2021 | 434,248.00 |